Liraglutide Injections Improved Rat Shoulder Range
A laboratory study found that targeted injections could help treat adhesive capsulitis in a rodent model.
Updated on Oct. 7, 2026 in Arthritis
Researchers have found that intra-articular liraglutide injections improved range of motion in a rat model of adhesive capsulitis. The study provides early evidence that this approach could influence how researchers approach musculoskeletal conditions.
Why it matters
This research aimed to test the anti-fibrotic potential of liraglutide, a medication commonly used for other health conditions, in treating frozen shoulder. It represents a preliminary step toward understanding whether such therapies can effectively reduce joint stiffness and fibrosis.
This preclinical study utilized 28 rats divided into groups to compare saline, triamcinolone, and two doses of liraglutide. While the findings showed statistically significant improvements in abduction angle at 3 weeks, this remains a preliminary investigation requiring further clinical testing.
The details
To evaluate the drug, researchers induced adhesive capsulitis in the rats through a 6-week immobilization period before administering a single intra-articular injection. The treatment groups demonstrated reduced capsular thickness and lower levels of fibronectin, which are key markers of the fibrotic tissue buildup that restricts joint movement. High-dose liraglutide specifically suppressed alpha-smooth muscle actin, suggesting a targeted effect on the cellular processes that cause tissue scarring.
Timeline
The initial shoulder immobilization phase lasted for 6 weeks.
Researchers observed improvements in abduction angle at the 3-week assessment point.
Health Landscape
This study contributes to the expanding body of research exploring the therapeutic potential of GLP-1 receptor agonists beyond metabolic health. By investigating their role in musculoskeletal fibrosis, researchers are testing whether existing therapies might be repurposed for complex tissue conditions.
These findings are strictly limited to a laboratory animal model and have no current application for human treatment or medical care. It remains important to discuss any concerns regarding shoulder stiffness or mobility with your doctor, who can provide guidance on evidence-based therapies.
The takeaway
This study suggests that liraglutide could influence fibrotic processes in a laboratory setting, but it is not a treatment for human use at this time. Always consult with a physician to explore proven interventions for shoulder pain or loss of motion rather than relying on early-stage animal data.
Further reading
For more information on the evolving treatment of joint conditions, visit our section on Arthritis.
Source note: This article includes information reported by Nature.
